SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Altimmune, Inc. is a clinical stage biopharmaceutical company, which focuses on the development of novel peptide-based therapeutics for the treatment of obesity and liver diseases. The company's lead product candidate, pemvidutide, is a GLP-1/glucagon dual receptor agonist that is being developed for the treatment of obesity and NASH. In addition, Altimmune is developing HepTcell, an immunotherapeutic designed to achieve a functional cure for chronic hepatitis B. The company was founded in 1997 and is headquartered in Gaithersburg, MD.

Altimmune Inc

Altimmune is trending as the community speculates on upcoming catalysts related to MASH and obesity treatments. Discussions revolve around the potential impact of recent FDA qualifications related to AI-driven analysis in liver biopsies, with many anticipating positive data readouts. Some traders are also eyeing a potential "golden cross" pattern and anticipating significant upward movement.

RAGE GUY (RAGE) is a cryptocurrency inspired by the Rage Guy meme, one of the earliest and most recognizable characters from internet rage comics. The project captures the cultural legacy of early meme history and brings it onto the blockchain in tokenized form. It is designed as a community-driven digital asset that celebrates internet culture, nostalgia, and the role memes play in shaping online communities.

Rage Guy

RAGE CRYPTO is trending as the community rallies around the return to OG memes and a growing sense of anticipation for upcoming developments. Discussions revolve around community building, with members expressing strong conviction and encouraging others to join before it's "too late." The focus remains on long-term potential and a collective effort to drive the project forward.

SAIHEAT Ltd. engages in the operation of cryptocurrency mining. It operates Bitcoin for its own account and provides full suite of services, purchase of mining machines, hosting service, and mining pool. The company was founded by Risheng Li on February 2, 2021, and is headquartered in Singapore.

SAIHEAT Ltd. - Ordinary Shares - Class A

SAIHEAT Ltd

SAIH is trending due to speculation around its small modular reactor (SMR) technology potentially being used by Amazon, fueling significant after-hours momentum and a breakout. The stock's low float is a key talking point, with many traders anticipating a potential short squeeze and comparing it to other recent parabolic runners. Community members are actively watching for continued volume and breakout levels, discussing its potential as a play in the AI, energy, and data center space.

Vor Biopharma, Inc. engages in developing cell therapies for treating cancer. It is a clinical-stage cell therapy company that combines a novel patient engineering approach with therapies to provide a single company solution for patients suffering from hematological malignancies. The company was founded by Aleks Radovic-Moreno and Siddhartha Mukherjee on December 30, 2015 and is headquartered in Boston, MA.

Vor Biopharma Inc

VOR is trending due to positive sentiment around a recent Phase 3 clinical study, although opinions are split on whether this will be a long-term catalyst or a short-lived pump, as some traders discuss an upcoming share offering and reverse split. Community members are weighing the potential for a short squeeze against concerns of dilution, with some highlighting institutional ownership and potential undervaluation. The stock's volatile price action and high short interest are fueling active discussions.

Exicure, Inc. develops therapeutics for immuno-oncology, genetic disorders and other indications based on its proprietary Spherical Nucleic Acid. The firm's product pipeline includes Cavrotolimod (AST-008) and XCUR-FXN. The company was founded by Chad A. Mirkin and Colby Shad Thaxton in June 2011 and is headquartered in Redwood City, CA.

Exicure Inc

XCUR is trending due to positive Phase 2 trial results for its cancer treatment, spurring excitement among investors. The community highlights the massive market potential and the stock's low float, which could lead to a short squeeze. However, some traders are wary of a potential offering this week, given the company's previous cash concerns.

AlphaTime Acquisition Corp. is a blank check company, which engages in the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses. The company was founded on September 15, 2021 and is headquartered in New York, NY.

AlphaTime Acquisition Corp

ATMC is trending following shareholder approval of its merger with HCYC Group, driving significant after-hours volume and price action. Community discussions highlight the stock's low float and potential for a short squeeze, with some drawing comparisons to other recent high-flying low float plays. Speculation is rampant regarding potential price targets, with many noting the possible impact of the merger on the company's valuation.

DaVita, Inc. engages in the provision of medical care services. It operates through the following two segments: US Dialysis and Related Lab Services, and Other-Ancillary Services and Strategic Initiatives. The US Dialysis and Related Lab Services segment offers kidney dialysis services in the United States for patients suffering from chronic kidney failure. The Other-Ancillary Services and Strategic Initiatives segment consist primarily of pharmacy services, disease management services, vascular access services, clinical research programs, physician services, direct primary care, end stage renal disease seamless care organizations, and comprehensive care. The company was founded in 1994 and is headquartered in Denver, CO.

DaVita Inc

DaVita ($DVA) is trending amid discussions about its relationship with Akebia Therapeutics ($AKBA) and potential impacts from new kidney disease treatments, with some traders pointing to trade alerts suggesting possible bullish reversals based on oversold conditions. Community members are scrutinizing Akebia's communications and awaiting DaVita's Q3 earnings report, speculating about potential adoption of new technologies and their effect on patient outcomes. Discussions also involve the potential for mergers and acquisitions within the dialysis space.

FMC Corp. is an agricultural sciences company, which engages in the provision of solutions to growers and development of pipeline in crop protection, plant health, agriculture, pest control, and turf management. It offers insect control products under the Rynaxypyr and Cyazypyr brands, herbicides under the Authority, Boral, Centium, Command, and Gamit brands, insecticides under the Talstar and Hero brands, flutriafol-based fungicides, and bionematicides under the Quartzo and Presence brands. The company was founded by John Bean in 1883 and is headquartered in Philadelphia, PA.

FMC Corp.

FMC is trending as the stock experiences a steep drop following a recent earnings report and lowered guidance, prompting discussions about its long-term viability and debt management. The community is analyzing the potential for a turnaround, with some viewing the current price as a buying opportunity due to the company's historical presence and oversold conditions, while others express concern over the dividend cut and overall financial health.

Norwegian Cruise Line Holdings Ltd. engages in the provision of cruise travel services. It offers cruise experiences for travelers with itineraries in Europe, Asia, Australia, New Zealand, South America, Africa, Canada, Bermuda, Caribbean, Alaska and Hawaii. Its brands include Norwegian Cruise Line, Oceania Cruises, and Regent Seven Seas Cruises. The company was founded in 1966 and is headquartered in Miami, FL.

Norwegian Cruise Line Holdings Ltd

NCLH is trending due to a recent downgrade from Goldman Sachs, sparking debate among investors about the company's prospects and analyst accuracy. Community members are actively discussing whether the stock is overbought and questioning the validity of analyst ratings, especially compared to JPM's outlook. Overall sentiment is mixed as some see a buying opportunity while others express frustration with the stock's performance.

The Mosaic Co. engages in the production and marketing of concentrated phosphate and potash crop nutrients. It operates through the following segments: Phosphates, Potash, and Mosaic Fertilizantes. The Phosphates segment is involved in the ownership and operation of mines and production facilities which produce concentrated phosphate crop nutrients and phosphate-based animal feed ingredients, and processing plants which produce concentrated phosphate crop nutrients. The Potash segment includes mining, processing, and selling potash. The Mosaic Fertilizantes segment focuses on mines, chemical plants, crop nutrient blending and bagging facilities, port terminals, and warehouses. The company was founded on March 25, 2004 and is headquartered in Tampa, FL.

Mosaic Company

Mosaic Company ($MOS) is trending as investors weigh the impact of potential potash production cuts and recent hurricane-related operational challenges. Community members are discussing the stock's undervaluation, high dividend yield, and potential for long-term growth in the agricultural sector. Also being considered is how commodity prices and broader market conditions might affect the stock's performance.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Geode Capital Management LLC Raises Stock Holdings in Rezolute, Inc. $RZLT

Geode Capital Management LLC increased its stake in Rezolute, Inc. (NASDAQ:RZLT - Free Report) by 201.7% during the 2nd quarter, according to the company in its most recent disclosure with the...

Traders Buy Large Volume of Put Options on Rezolute (NASDAQ:RZLT)

Rezolute, Inc. (NASDAQ:RZLT - Get Free Report) was the recipient of some unusual options trading on Thursday. Stock traders purchased 2,877 put options on the stock. This represents an increase of...

Stonepine Capital Management LLC Takes Position in Rezolute, Inc. $RZLT

Stonepine Capital Management LLC bought a new stake in shares of Rezolute, Inc. (NASDAQ:RZLT - Free Report) during the second quarter, according to the company in its most recent filing with the...

How Much Upside is Left in Rezolute (RZLT)? Wall Street Analysts Think 56.58%

The consensus price target hints at a 56.6% upside potential for Rezolute (RZLT). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Cantor Fitzgerald Expects Stronger Earnings for Rezolute

Rezolute, Inc. (NASDAQ:RZLT - Free Report) - Investment analysts at Cantor Fitzgerald upped their FY2026 earnings per share estimates for shares of Rezolute in a research note issued on Monday...

All You Need to Know About Rezolute (RZLT) Rating Upgrade to Buy

Rezolute (RZLT) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Can Rezolute (RZLT) Climb 49.4% to Reach the Level Wall Street Analysts Expect?

The consensus price target hints at a 49.4% upside potential for Rezolute (RZLT). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Rezolute (NASDAQ:RZLT) Shares Down 7.9% - Here's Why

Rezolute (NASDAQ:RZLT) Shares Down 7.9% - Time to Sell...

HC Wainwright Has Weak Estimate for Rezolute FY2030 Earnings

Rezolute, Inc. (NASDAQ:RZLT - Free Report) - Analysts at HC Wainwright lowered their FY2030 EPS estimates for Rezolute in a note issued to investors on Friday, November 7th. HC Wainwright analyst D...

Rezolute (NASDAQ:RZLT) Announces Quarterly Earnings Results, Beats Expectations By $0.09 EPS

Rezolute (NASDAQ:RZLT - Get Free Report) issued its quarterly earnings results on Thursday. The company reported ($0.18) earnings per share for the quarter, topping the consensus estimate of ($0.27...

Rezolute, Inc. operates as a biopharmaceutical company, which engages in the development of drug therapies for patients with metabolic and orphan diseases. The firm's antibody therapy, ersodetug, is designed to treat all forms of hyperinsulinism. The company was founded by Nevan Charles Elam, Ho Young Huh, and Sankaram Mantripragada in March 2010 and is headquartered in Redwood City, CA.

Fiscal Period	Estimated	Reported	Surprise	Result
Q2 '26	-$0.19	--	--	N/A
Q1 '26	-$0.24	-$0.18	25.69%	BEAT
Q4 '25	-$0.22	-$0.26	-18.56%	MISSED
Q3 '25	-$0.23	-$0.27	-18.07%	MISSED
Q2 '25	--	-$0.22	--	N/A

RZLT
Rezolute Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Upcoming Earnings: Q2 '26

Historical Earnings

Latest RZLT News

RZLTRezolute Inc